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Background: Although procurement consumes nearly 40% of Global Fund’s money, no analyses have been
published to show how costs vary across regions and time. This paper presents an analysis of malaria-related
commodity procurement data from 79 countries, as reported through the Global Fund’s price and quality
reporting (PQR) system for the 2005–2012 period.
Methods: Data were analysed for the three most widely procured commodities for prevention, diagnosis and
treatment of malaria. These were long-lasting insecticide-treated nets (LLINs), malaria rapid diagnostic tests (RDTs)
and the artemether/lumefantrine (AL) combination treatment. Costs were compared across time (2005–2012),
regions, and between individual procurement reported through the PQR and pooled procurement reported
through the Global Fund’s voluntary pooled procurement (VPP) system. All costs were adjusted for inflation and
reported in US dollars.
Results: The data included 1,514 entries reported from 79 countries over seven years. Of these, 492 entries were
for LLINs, 330 for RDTs and 692 for AL. Considerable variations were seen by commodity, although none showed
an increase in cost. The costs for LLINs, RDTs and AL all dropped significantly over the period of analysis. Regional
variations were also seen, with the cost for all three commodities showing significant variations. The median cost
for a single LLIN ranged from USD 4.3 in East Asia to USD 5.0 in West and Central Africa. The cost of a single RDT
was lowest in West and Central Africa at US$ 0.57, and highest in the Latin American region at US$ 1.1. AL had
the narrowest margin of between US$ 0.06 per tablet in sub-Saharan Africa and South Asia, and US$ 0.08 in the
Latin American and Eastern Europe regions.
Conclusion: This paper concludes that global procurement costs do vary by region and have reduced overall
over time. This suggests a mature market is operating when viewed from the global level, but regional variation
needs further attention. Such analyses should be done more often to identify and correct market insufficiencies.
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Malaria infected 219 million people leading to 660,000
deaths in 2010 [1]. The numbers have reduced gradually
over the past decade. It is estimated, for instance, that
malaria deaths have reduced by a third in sub-Saharan
Africa over the period [1]. These successes can be attrib-
uted to the combined efforts of governments, civil soci-
ety and private sector, with support from bilateral and* Correspondence: frankfula@yahoo.com
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for malaria, contributing nearly half of all international
financing for the disease [2]. Between 2002–2012, Global
Fund financing helped provide over 310 million
insecticide-treated nets for malaria control [2]. It is esti-
mated that more than 260 million malaria cases were
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tries goes towards procurement, making it a major
player in the market for commodities. To ensure the
money is used efficiently, the Global Fund introduced
a price reporting mechanism, the Price and Quality
Reporting (PQR) system, in 2005 [3], and a voluntary
pooled procurement (VPP) system in 2009 [4].
The PQR is a web-based system that collects procure-
ment data for anti-malarials, bed nets and malaria rapid
diagnostic tests (RDTs), as well as selected HIV and TB
commodities. Grant recipients enter procurement data
on delivery of each consignment, with non-compliers
facing the risk of getting a poor grant rating, and lower
subsequent disbursements [5,6]. The VPP, on the other
hand, was designed to lower costs through pooled pur-
chasing. Under the system, VPP agents place orders on
behalf of countries, and report procurement information
directly to the Global Fund. VPP procurement informa-
tion is not entered into the PQR system.
While the PQR has collected large amounts of data,
little analyses have been published to show how procure-
ment costs vary by region and time. Past medicine price
analyses have focused on comparing prices paid by
consumers across countries (country-level comparison)
rather than comparing procurement costs across coun-
tries and regions (global-level comparison). This paper
describes procurement cost trends for selected malaria
commodities over the seven-year period.
Methods
Three Global Fund datasets were used: one containing
PQR- data showing commodity costs for individual
country procurement, the second reporting data for pro-
curements done through the VPP system, and the final
one containing information on the location (region) of
grant recipients.
The Global Fund provides grants across 8 regions: East
Asia and the Pacific (EAP), Eastern Europe and Central
Asia (EECA), Latin America and the Caribbean (LAC),
Middle East and North Africa (MENA), South Asia,
sub-Saharan Africa -East Africa (SSA-EA), sub-Saharan
Africa (SSA-SA) and sub-Saharan Africa- West and cen-
tral Africa (SSA-WCA).
Three commodities were subsequently selected for
analysis: long-lasting insecticide-treated nets (LLINs),
RDTs and artemether/lumefantrine (120 mg/20 mg).
The three were the most commonly procured commod-
ities for prevention, diagnosis and treatment of malaria
respectively.
Initial inspection revealed data outliers, necessitating the
use of medians and interquartile ranges (IQRs), rather
than means. Past analyses of commodity prices have also
used medians [7]. All costs were reported in USD, and
were adjusted for inflation using World Bank providedvalues [8]. Extreme values deemed to arise from data entry
errors were omitted from the analyses (omitted values
were less than 1% of the analysed data).
Unit costs calculated were the cost of a single tablet
for AL; the cost of a bed net and the cost of a single
RDT. Information on RDT brands was unavailable,
meaning unit cost calculations could not be done for kits
with the same exact specifications. Caution should,
therefore, be exercised when interpreting the results for
this commodity. Scatter plots of unit costs were plotted
against time (2005–2012), and corresponding regression
coefficients and p-values reported. A linear regression
line of the unit cost against time was superimposed on
the scatter plots to illustrate the trend. Regional median
prices were calculated and presented in tables, with cor-
responding IQR values, and p-values showing the level
of significance of the regional variations.
Finally, PQR reported costs were compared to those
reported through the VPP. We compared the regression
coefficients of PQR and VPP costs for the three com-
modities to test the null hypothesis Ho: Coefp = Coefv,
where Coefp is the regression coefficient for PQR costs,
and Coefv is the regression coefficient for VPP costs. A
model was then fitted including the variables PQR, time
and an interaction term representing the product of
PQR and time. The interaction term PQR-time was used
to test the null hypothesis, and findings discussed. Ana-
lyses were done using STATA version 12 (Stata Corp,
Texas, USA).
Results
There were 1,514 entries from 79 countries spread
across the eight Global Fund regions. Of the 1,514
entries, 492 were for LLINs, 330 for RDTs and 692 for
the AL (20 mg + 120 mg) combination. These entries
included both PQR and VPP reported data. There was
an overall annual increase in number of purchases re-
ported through the PQR, with the 2003 – 2005 period
having less than 100 entries, and the period after 2011
having more than 400 entries per year.
Comparing median costs by Global Fund region
The median cost for LLINs ranged from USD 4.3 in East
Asia to USD 5.0 in the SSA-WCA region (Table 1). For
RDTs, median costs were lowest in SSA-WCA 0.57, and
highest in the LAC region (USD 1.1, IQR 0.82-1.6). The
EECA region had only one purchase reported over the
period of analysis. However, brand details were not pro-
vided, making it impossible to understand how unit costs
varied for malaria RDTs with similar specifications. The
cost of AL also showed variations across the eight regions,
with the highest unit costs being reported in the LAC and
EECA regions (both USD 0.08). The Kruskal-Wallis test
showed that the regional median cost variations were
Table 1 Median and inter-quartile costs (2005–2012) for commodities by GF region
Global fund region Median costs (number of purchases) (inter-quartile ranges) for the 2005–2012 period
LLINs Malaria test kits AL anti-malarial
East Asia/Pacific 4.3 (92) (3.9-5.2) 0.63 (59) (0.55-0.76) 0.07 (115) (0.06-0.07)
Eastern Europe/Central Asia 6.1 (19) (5.5-7.1) 0.80 (1) (0.80-0.80) 0.08 (5) (0.06-0.08)
Latin America/Caribbean 5.2 (32) (4.0-6.0) 1.1 (29) (0.82-1.6) 0.08 (20) (0.06-0.09)
North Africa/Middle East 4.8 (59) (3.5-6.1) 0.64 (22) (0.56-0.81) 0.07 (24) (0.06-0.07)
South Asia 5.2 (59) (4.6-5.7) 0.61 (59) (0.32-0.83) 0.06 (27) (0.06-0.08)
SSA: East Africa 6.0 (95) (4.8-7.8) 0.87 (72) (0.56-1.1) 0.06 (206) (0.06-0.07)
SSA: Southern Africa 5.5 (20) (5.1-6.2) 0.68 (23) (0.55-0.77) 0.06 (81) (0.06-0.07)
SSA: West and Central Africa 5.5 (80) (4.5-6.6) 0.57 (57) (0.46-0.97) 0.06 (142) (0.06-0.07)
p- Value (Kruskal-Wallis Test) p < 0.001 p < 0.001 p = 0.001
Wafula et al. Malaria Journal 2013, 12:466 Page 3 of 7
http://www.malariajournal.com/content/12/1/466significant at the 95% level across all three commodities
(Table 1).
Procurement cost trends over the period of analysis
(2005–2012)
The cost trends varied across commodities, with LLINs
and AL showing significantly large reductions over the
period (p < 0.001 for both, see Figures 1 and 2), while
RDTs showed a relatively lower but still significant
decline over the period (p = 0.04, see Figure 3).
Comparing cost trends for VPP and non-VPP procurement
Analyses for VPP costs were only done for the period the
VPP was in existence (period VPP data were available,
2009–2012). For this period, both the PQR and VPP costs
showed significant declines for RDTs (p = 0.001 and
p = 0.02 for PQR and VPP respectively, Figure 4) and





















































Unit Cost Fitted T
Coef.=.002 (P<.001)
Unit Costs of Long-Lasting In
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Figure 1 Unit costs of LLINs over time.However, findings were mixed for AL, with PQR costs
showing a significant decline (p = 0.02) while the change
in VPP costs was not significant at the 95% level (p = 0.16,
Figure 6). Comparing PQR and VPP trends showed that
the differences were not statistically significant across all
three commodities (p = 0.9, p = 0.3 and p = 0.6 for LLINs,
AL and RDTs respectively, see Figures 4, 5, and 6).
Discussion
In a well functioning market, prices for commodities fall
as newer and more sophisticated ones enter the market.
However, health care markets are well known to have
higher risks of monopolization and information flow inad-
equacies, both of which may lead to reduced supply and
increased prices [9,10]. For this reason, prices for health
care commodities should be monitored continuously, and
corrections made where market failures emerge. This
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Unit Cost Fitted Trend 95% CI Fitted trend
Coef.=-.000 (P<.001)
Unit Costs (per tablet) of Artemether + Lumefantrine - FDC over Time
R-squared=.160
Figure 2 Unit costs of the artemether/lumefantrine combination over time.
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for three key malaria commodities.
The analysis found significant declines in cost trends
over the seven years, with LLINs and AL showing larger
declines than RDTs. The drop in the cost for LLINs pos-
sibly reflects a rise in competition and demand that
followed an overall increase in malaria funding over the
period. According to WHO, international funding for
malaria increased from below US$ 100 million in 2000
to US$ 1.71 billion in 2010 [1]. Domestic funding was
also reported to have increase in most countries over the
period.
Low LLIN prices are not however a direct reflection of
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R-squared=.014
Figure 3 Unit costs of malaria RDTs over time.encouraged to consider longevity alongside cost [11].
Higher initial costs may reduce the cost-per-year and re-
sult in more savings if the nets have a considerably longer
lifespan [11,12]. The Global Fund has been criticized for
overemphasizing low unit cost at the expense of longevity
(although the Global Fund promotes procurement of the
lowest priced WHO-prequalified LLINs, longevity of pre-
qualified nets also varies) [11]. Future analyses should look
at the price benefits of procuring LLINs of varying dur-
ability across different settings. This could not be done be-
cause brand information was not provided.
The cost of AL also showed a significant decline over
the period of analysis. This may be attributed mainly to
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PQR PQR fitted trend 95% CI PQR fitted trend
VPP VPP fitted trend 95% CI VPP fitted trend
PQR Coef.=-.000 (P=.001)
Unit Costs of Malaria Rapid Diagnostic Tests over Time
VPP Coef.=-.000 (P=.017)
PQR vs VPP (fitted trends) P=.584
Figure 4 Comparing costs of direct and VPP procurement of RDTs.
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lated that Novartis would supply AL to public sector
buyers at cost price [13]. Several rounds of price negoti-
ations between Novartis and the Global Fund over the
period resulted in further declines in AL prices, which
is reflected in the observed trends. These negotiations
explain why AL procurement costs did not increase in
the face of a volatile market for the artemisinin raw ma-
terial over the period of analysis [14].
Another factor that may have contributed to the AL
procurement cost decline was the overall growth in the
market for ACTs. The number of WHO-prequalified
ACT manufacturers rose from one manufacturer produ-
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PQR Coef.=-.003 (P<.001)
Unit Costs of Long-Lasting I
VPP Coef.=-.003 (P<.001)
PQR vs VP
Figure 5 Comparing costs of direct and VPP procurement of LLINs.at least 11 different ACT formulations by 2011 [15].
Growth in demand was also seen, with the number of
ACT doses purchased by donors increasing from 11.2 mil-
lion to 217 million between 2005 and 2010 [15]. Costs are,
however, unlikely to drop much further, as production
processes for ACT are believed to be optimum [16]. Fur-
ther cost reductions may require the introduction of new
combination molecules.
Unlike LLINs and AL, the cost for RDTs only showed
a mild decline over the period. This result must, how-
ever, be interpreted with caution, as information on
brand names was unavailable. Unlike the other two com-
modities, RDTs vary considerably, from simple kits
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PQR PQR fitted trend 95% CI PQR fitted trend
VPP VPP fitted trend 95% CI VPP fitted trend
PQR Coef.=.000 (P=.023)
Unit Costs (per tablet) of Artemether + Lumefantrine - FDC over Time
VPP Coef.=-.000 (P=.164)
PQR vs VPP (fitted trends) P=.273
Figure 6 Comparing costs of direct and VPP procurement of AL.
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and Plasmodium vivax [17]. Not having this information
meant inference could not be made on whether pro-
cured kits were of the same exact specifications.
The slight decline in the overall RDT costs is nonethe-
less positive, especially considering the growing import-
ance of diagnostic confirmation. RDTs have been linked
to better treatment and reduced wastage of medicines
[18]. However, while demand for AL is expected to fall
with the shrinking malaria map, demand for RDTs is
likely to remain high, particularly in areas where fevers
are common [16]. This underscores the importance of
pursuing even lower prices for RDTs.
There were significant regional variations in the cost
for all three commodities. These variations may have re-
sulted from countries procuring commodities from dif-
ferent suppliers located across different countries.
Comparing PQR and VPP procurement showed pooled
procurement to have some benefit for RDTs and AL,
although the differences in cost were not significant at the
95% level. However, as the VPP was only introduced in
2009, analysis could only be done over a three-year period.
The marginal price benefit seen for RDTs and LLINs
agrees with analyses by the Global Fund, which showed
VPP prices to be either at par, or slightly lower than PQR
prices [4,19]. However, the significance of the price differ-
ence would only become clear after a longer period of
VPP usage. It should, nonetheless, be noted that the VPP
has other potential benefits besides cost reduction. These
include increased transparency in procurement, improved
payment terms for countries and better availability of
commodities [19].
There were some limitations in the analysis. First, only
one type of ACT was included in the analysis, meaningthe patterns may have differed if another combination
had been used. The decision to only include the most
procured ACT (AL) was informed by the need to avoid
introducing additional variability that may come with
combining products of different composition under one
analysis. However, future analyses should consider look-
ing at other ACT combinations, as well as differentiating
between LLINs and RDTs of different quality.
Another major limitation was the presence of some
outliers believed to result from data entry errors. This is
a problem that the Global Fund has recognized in the
past [3]. While measures such as omitting extreme
values and using medians would have minimized the
outlier effect, the possibility that data entry errors may
have biased the results in one direction or the other can-
not be ruled out. Another possible cause of bias was low
data availability, especially prior to 2008. There was no
way of exploring whether transactions that were captured
differed systematically from those that were not captured
during the early years of the PQR. It is expected that more
data will be captured as the PQR system improves over
time. Already, there has been a progressive increase in
data captured in the PQR system across all commodities,
with less than 100 total annual entries from 2003 – 2005
rising to over 4000 per year since 2011.
When doing analysis for AL, the pack sizes were not fac-
tored in. This may have caused some slight bias, especially
where countries changed their AL procurement prefer-
ence over time (for instance, changing from smaller
(pediatric) pack sizes to larger (adult) pack sizes or the re-
verse. However, this would have little public health signifi-
cance, as the same AL tablets (20 mg + 120 mg) are used
to treat adults and children (variations only come in the
number of tablets administered).
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factors. However, the role of the Global Fund and other
bilateral and multilateral health initiatives cannot be
overlooked, as they have contributed substantially to in-
creased demand, lowered procurement costs and stabi-
lized markets. As more data become available, research
should describe the variations in greater depth, including
the effect of the type of procuring organization (whether
government or non-government), order lead times, pro-
curement volumes and shipment or transport costs.
Future analyses should also examine the effect of using
the VPP system over longer periods of time.
Conclusions
The analysis showed the value of the PQR in assessing
regional and temporal cost trends. The data can inform
policy on how well global markets are working. As the
Global Fund and other donors continue supporting the
fight against the three diseases, it is important that every
caution is taken to ensure resources are used in the best
way possible. By doing such analyses, inadequacies can
be identified early and appropriate strategies developed.
Future analyses should describe the causes of variations
in greater depth, and assess the effectiveness of the VPP
system over a longer period of time.
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